Pharma: Looking to settle - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: Looking to settle

Nov 13, 2007

Since CY05, when generic companies worldwide were rocked on their heels by the substantial price erosion that they faced on their base business, the pricing pressure has not shown significant signs of receding. That said, the pricing pressure is now more brutal on new molecules losing patents than the base business, where prices have more or less stabilised. Thus, to counter these pressures global generic companies including Indian companies are focusing on niche product opportunities, which include challenging patents (Para IV filings) and products in therapeutic areas where there is lesser competition such as biologics, oncology, controlled substances and the like. As far as Para IV filings go, it is getting increasingly difficult for generic companies to secure that lucrative 180-exclusivity window while the legal costs are mounting. Hence, of late the focus has shifted to settling the patent lawsuits outside the court. In this article, we shall examine some of the positives and the challenges that this strategy involves.

The positives...
Revenue potential: The biggest positive that can accrue to the challenging company by settling the patent suit outside the court is the certainty with respect to the exclusivity period. While the launch of the generic drug will get delayed, the challenging company, nevertheless, gets the opportunity to launch its generic version a few months before the scheduled patent expiry with no other generic company present. This enables the challenging company to generate substantial revenues and profits with an element of certainty attached to it. Patent settlements are also beneficial to generic players in cases where the revenue potential is considerably lesser due to many players vying for a slice of the drug's revenues.

Mitigating risks: On an average, patent challenges entail sizeable legal costs with no clear visibility in terms of revenues. Plus there is tremendous uncertainty associated with the same. Hence, out-of-court settlements mean that pending lawsuits get dropped obviating the need to incur more legal expenses. Besides this, the certainty of revenues from a particular drug gets more pronounced and the costs associated with legal matters no longer eat into the generic company's profitability.

The challenges...
However, patent settlements are not without their share of challenges, some of which are enumerated below:

Approval from the FTC: Patent settlements generally come under the purview of the Federal Trade Commission (FTC), which could curtail the agreement if it feels that the settlement is anti-competitive in nature. Besides this, settlement deals are likely to be regulated to a greater degree due to public interest and consumer pressure. For instance, consumer groups could file lawsuits against the settling parties if they feel that the agreement would lead to a considerable delay in generic launches. To put things in perspective, Sanofi-Aventis and BMS had reached a settlement deal with Apotex for the former's blockbuster drug 'Plavix', which got rejected by the FTC.

Competition sets in: Obviously, while settlement deals enable the challenging company to enjoy exclusivity benefits, the same is short-term in nature as the period does not extend beyond six months, after which generic competition sets in and prices erode sharply. Also, one cannot take a call on which drugs the challenging company will settle its lawsuits outside court and hence uncertainty exists to that extent.

To conclude...
Of late, domestic companies such as Ranbaxy and Dr.Reddy's, which are pretty active on the Para IV filing front, have been aiming to settle patents to lend some semblance of certainty to their overall performance. This is given the fact that the generic markets of US and certain countries of Europe have become highly competitive in recent times. While Ranbaxy has settled cases related to drugs 'Valtrex', 'Cephalon' and the most recent one 'Flomax' with their respective innovator companies, Dr.Reddy's has been successful in settling for the drug 'Imitrex'. Thus, settling a patent challenge suit is a smart strategy if the risk-reward ratio is skewed towards the former. As mentioned earlier, this particularly reduces the risk of incurring additional legal costs, which would otherwise have dented the profitability of companies.


Equitymaster requests your view! Post a comment on "Pharma: Looking to settle". Click here!

  

More Views on News

ASTRAZENECA PHARMA Share Price Up by 6%; BSE HEALTHCARE Index Up 4.1% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

ASTRAZENECA PHARMA share price is trading up by 6% and its current market price is Rs 4,548. The BSE HEALTHCARE is up by 4.1%. The top gainers in the BSE HEALTHCARE Index are ASTRAZENECA PHARMA (up 6.3%) and DR. REDDYS LAB (up 9.1%). The top losers are FORTIS HEALTHCARE (down 0.1%) and ALEMBIC PHARMA (down 0.4%).

GRANULES INDIA Share Price Up by 5%; BSE HEALTHCARE Index Up 4.5% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

GRANULES INDIA share price is trading up by 5% and its current market price is Rs 385. The BSE HEALTHCARE is up by 4.5%. The top gainers in the BSE HEALTHCARE Index are GRANULES INDIA (up 5.0%) and DR. REDDYS LAB (up 8.8%). The top losers are ALEMBIC PHARMA (down 0.1%) and GSK PHARMA (down 0.3%).

J.B.CHEMICALS at All Time High; BSE HEALTHCARE Index Up 4.3% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

J.B.CHEMICALS share price has hit an all time high at Rs 1,148 (up 7.2%). The BSE HEALTHCARE Index is up by 4.3%. Among the top gainers in the BSE HEALTHCARE Index today are J.B.CHEMICALS (up 7.2%) and ABBOTT INDIA (up 0.8%). The top losers include FORTIS HEALTHCARE (down 0.2%) and PIRAMAL ENTERPRISES (down 0.7%).

GLENMARK PHARMA Share Price Up by 5%; BSE HEALTHCARE Index Up 4.5% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

GLENMARK PHARMA share price is trading up by 5% and its current market price is Rs 518. The BSE HEALTHCARE is up by 4.5%. The top gainers in the BSE HEALTHCARE Index are GLENMARK PHARMA (up 5.0%) and DR. REDDYS LAB (up 8.8%). The top losers are ALEMBIC PHARMA (down 0.1%) and GSK PHARMA (down 0.3%).

LAURUS LABS LTD Share Price Up by 5%; BSE HEALTHCARE Index Up 3.0% (Market Updates)

Sep 18, 2020 | Updated on Sep 18, 2020

LAURUS LABS LTD share price is trading up by 5% and its current market price is Rs 1,480. The BSE HEALTHCARE is up by 3.0%. The top gainers in the BSE HEALTHCARE Index are LAURUS LABS LTD (up 5.2%) and J.B.CHEMICALS (up 5.0%). The top losers are PROCTER & GAMBLE HEALTH (down 0.1%) and DR. LAL PATHLABS LTD (down 0.6%).

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 18, 2020 02:05 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS